Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Lunsumio Velo Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentAnthemPolicy CC-0232

    Lunsumio (mosunetuzumab-axgb) and Lunsumio Velo (mosunetuzumab-axgb) - Coverage Criteria

    Customize your policy alerts

    Sign up for Anthem Policy CC-0232 alerts

    Get alerted when Policy CC-0232 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical criteria and coding guidance governing prior authorization and coverage considerations for Lunsumio (IV) and Lunsumio Velo (SC) for treatment of relapsed/refractory follicular lymphoma and certain NCCN 2A B-cell lymphoma indications; applies to Anthem medical benefit reviews.

    Policy Summary
    PayerAnthem
    PolicyLunsumio (mosunetuzumab-axgb) and Lunsumio Velo (mosunetuzumab-axgb) - Coverage Criteria
    Policy CodePolicy CC-0232
    Change TypeAdded product (Velo) and expanded NCCN 2A combination use
    Effective Date
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionObtain prior authorization and submit documentation of diagnosis, prior systemic therapies, line of therapy, and planned single-agent or combination use with polatuzumab as applicable.
    SourceLink
    POLICY UPDATE CHANGES

    Added Lunsumio Velo to criteria and to HCPCS J9350 and added ICD-10-CM C83.10-C83.19.

    Updated criteria to include new NCCN 2A recommended use with Polivy for Mantle Cell Lymphoma and use as combination therapy with polatuzumab-vedotin-piiq for second-line+ therapy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J9350HCPCS code
    >=2Prior therapy requirement
    NCCN 2ASupport level
    Black boxBoxed warning

    Coverage Criteria for Lunsumio and Lunsumio Velo

    Approval criteria

    Requests may be approved if ONE of the following branches is satisfied:

    Approval pathways

    • Pediatric approval: Individual is under 19 years of age

      Pediatric criterion

    • Adult follicular lymphoma single-agent: Individual has a diagnosis of relapsed, refractory, or progressive follicular lymphoma AND has received two or more lines of systemic therapy AND is using Lunsumio as a single agent>= 2 prior systemic therapies

      Accelerated approval based on response rate; continued approval contingent on confirmatory trial

    • NCCN 2A combination use with Polivy: Individual has one of the specified relapsed/refractory B-cell lymphomas (Diffuse Large B-Cell Lymphoma; High Grade B-Cell Lymphoma; HIV-Related B-Cell Lymphomas; Post-Transplant Lymphoproliferative Disorders; Progressive Mantle Cell Lymphoma after prior covalent BTKi therapy) AND is using as second-line or subsequent therapy AND is using in combination with polatuzumab-vedotin-piiq (Polivy)second-line or later

      NCCN 2A recommended use

    Denial condition note: Requests for Lunsumio may not be approved when the above criteria are not met and for all other indications.

    Denial triggers per policy

    Requests for Lunsumio (mosunetuzumab-axgb) and Lunsumio Velo (mosunetuzumab-axgb) may not be approved when the above clinical criteria are not met. Denials will be issued for requests that do not satisfy one of the specified approval pathways (pediatric approval OR adult follicular lymphoma single‑agent pathway OR NCCN 2A combination use with polatuzumab-vedotin-piiq).

    Use of Lunsumio for indications outside those listed in this policy — including requests that fail to meet required age, diagnosis, prior lines of systemic therapy (e.g., >= 2 where specified), or the required single‑agent versus combination with polatuzumab-vedotin-piiq conditions — is not approved under this criterion and may be denied.

    Covered Regimens and Combination Use

    RegimenIndication / CriteriaCoverage
    Lunsumio (mosunetuzumab-axgb) or Lunsumio Velo (subcutaneous)
    Relapsed, refractory, or progressive follicular lymphoma in adults AND prior receipt of two or more lines of systemic therapy; used as single‑agent therapy. Accelerated approval based on response rate; continued approval may be contingent on confirmatory trial results.
    covered_with_criteria
    RegimenIndication / CriteriaCoverage
    Lunsumio (mosunetuzumab-axgb) in combination with Polivy (polatuzumab-vedotin-piiq)
    Relapsed or refractory Diffuse Large B‑Cell Lymphoma, High‑Grade B‑Cell Lymphoma, HIV‑Related B‑Cell Lymphomas, Post‑Transplant Lymphoproliferative Disorders, or Progressive Mantle Cell Lymphoma after prior covalent BTKi therapy; used as second‑line or subsequent therapy. Supported by NCCN 2A recommendation and phase 1b/2 dose‑expansion data for large B‑cell lymphoma.
    covered

    Coding and Diagnosis Codes

    HCPCSHCPCS
    J9350Injection, mosunetuzumab-axgb, 1 mg [Lunsumio (IV), Lunsumio Velo (SC)]
    ICD-10-CM diagnosis codesICD-10
    B20Human immunodeficiency virus [HIV] disease (listed for HIV-related B-cell lymphomas)
    C83.10-C83.19Mantle cell lymphoma (range added)
    C83.30-C83.38Diffuse large B-cell lymphoma
    C83.398Diffuse large B-cell lymphoma of other extranodal and solid organ sites
    C83.80-C83.89Other non-follicular lymphoma
    C85.10-C85.19Unspecified B-cell lymphoma
    C85.20-C85.29Mediastinal (thymic) large B-cell lymphoma
    D47.Z1Monoclonal B-cell lymphocytosis and related (listed)
    Prior lines of systemic therapy
    Required prior lines>= 2 prior systemic therapies
    Applies to indicationRelapsed or refractory follicular lymphoma (adult)
    Line-of-therapy contextThird-line or subsequent when used as single agent

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Lunsumio (mosunetuzumab-axgb) and Lunsumio Velo (mosunetuzumab-axgb). Requests will be reviewed against the clinical criteria (diagnosis, prior lines of therapy, single-agent vs combination use, age) and may be approved only when those specific criteria are met.

    • Submit supporting documentation: diagnosis (relevant ICD-10 codes), prior systemic therapies, treatment intent, and clinical notes.
    • HCPCS: J9350 (Injection, mosunetuzumab-axgb, 1 mg)
    Step Therapy

    Dosing Safety / Step‑Up Dosing Required

    Lunsumio carries a boxed warning for cytokine release syndrome (CRS). Initiation must follow the recommended step‑up dosing schedule to reduce CRS risk. Hold or permanently discontinue Lunsumio based on CRS severity per prescribing information.

    • Ensure treatment plan documents planned step-up dosing and monitoring for CRS.
    • Educate staff and patient on CRS signs/symptoms and management pathways prior to initiation.

    Line-of-Therapy Criteria

    third-line | subsequent

    Third-line or subsequent (Follicular lymphoma): Used after two or more lines of systemic therapy>=2 prior systemic therapies

    Single-agent use required for this follicular lymphoma indication (accelerated approval)

    second-line | subsequent

    Second-line or subsequent (NCCN 2A combination): Used as second-line and subsequent therapy in listed NCCN 2A B-cell lymphomas when combined with polatuzumab-vedotin-piiq (Polivy)second-line or later

    Indication supported by NCCN 2A; combination required per criteria

    Background and Clinical Context

    Lunsumio is a T‑cell engaging bispecific antibody that directs T cells to CD20‑expressing B cells. It is used clinically as a single‑agent for relapsed/refractory follicular lymphoma after >= 2 prior systemic therapies (accelerated approval) and, per NCCN 2A guidance, may be used in combination with polatuzumab-vedotin-piiq (Polivy) for certain relapsed/refractory B‑cell lymphomas when given as second‑line or subsequent therapy. The therapy carries a boxed warning for cytokine release syndrome, and initiation should follow recommended step‑up dosing with appropriate monitoring and withholding or discontinuation as indicated by CRS severity.

    Definitions

    Complete Response or Complete Remission
    DefinitionThe disappearance of all signs of cancer as a result of treatment; also called complete remission; does not indicate the cancer has been cured.
    AbbreviationCR (Complete Response)
    Clinical noteUsed as an efficacy endpoint supporting accelerated approval for follicular lymphoma indication.
    Relapse or recurrence / Disease Progression
    DefinitionAfter a period of improvement when disease could not be detected, the return of signs and symptoms of illness or disease; for cancer, may recur at the original site or elsewhere.
    SynonymRelapse or recurrence

    Policy Revision History

    2026-02-20Annual Review - materialLatest

    Added Lunsumio Velo to the criteria and to HCPCS J9350; updated criteria to include new NCCN 2A recommended use with Polivy for Mantle Cell Lymphoma and added ICD-10-CM C83.10-C83.19.

    2025-05-16Select Review - material

    Added NCCN 2A recommendations for R/R HIV-related B-cell lymphomas and post-transplant lymphoproliferative disorders; removed CAR-T and transplant non-candidate requirements; coding updated with ICD-10-CM B20, C83.80-C83.89, C85.20-C85.29, D47.Z1.

    2025-02-21
    Policy Summary
    PayerAnthem
    PolicyLunsumio (mosunetuzumab-axgb) and Lunsumio Velo (mosunetuzumab-axgb) - Coverage Criteria
    Policy CodePolicy CC-0232
    Change TypeAdded product (Velo) and expanded NCCN 2A combination use
    Effective Date
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionObtain prior authorization and submit documentation of diagnosis, prior systemic therapies, line of therapy, and planned single-agent or combination use with polatuzumab as applicable.
    SourceLink
    On This Page
    Coverage Criteria for Lunsumio and Lunsumio VeloCovered Regimens and Combination UseCoding and Diagnosis CodesProvider Actions and Authorization RequirementsLine-of-Therapy CriteriaBackground and Clinical ContextDefinitionsPolicy Revision History
    Clinical implication
    Indicates need for subsequent lines of therapy per coverage criteria.
    Refractory Disease
    DefinitionIllness or disease that does not respond to treatment.
    Clinical implicationClassified as refractory when disease fails to respond, informing eligibility for Lunsumio under relapsed/refractory criteria.
    ContrastDistinct from progression or relapse, which describe disease return or growth after prior improvement.
    Annual Review - material

    Added NCCN 2A recommendations for Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma; coding updated with ICD-10-CM C83.30-C83.38, C83.398, C85.10-C85.19.

    2024-02-23Annual Review

    Included progressive disease per NCCN; coding reviewed with no changes.

    2023-02-24Annual Review / Creation

    Created new clinical criteria document for Lunsumio; initial coding additions and later effective changes on 2023-07-01 added HCPCS J9350 and ICD-10-CM C82.00-C82.99.